{
      "brief_title": [
            "phase",
            "iia",
            "multicenter",
            "study",
            "ass",
            "tolerability",
            "pharmacokinetics",
            "zibotentan",
            "give",
            "orally",
            "daily",
            "subject",
            "metastatic",
            "prostate",
            "cancer"
      ],
      "brief_summary": [
            "primary",
            "purpose",
            "study",
            "determine",
            "safest",
            "dose",
            "zibotentan",
            "men",
            "prostate",
            "cancer"
      ],
      "condition": [
            "metastasis",
            "neoplasm"
      ],
      "intervention_type": [
            "drug"
      ],
      "intervention_name": [
            "mg"
      ],
      "description": [
            "2",
            "x",
            "10",
            "mg",
            "2",
            "x",
            "mg",
            "oral",
            "tablet",
            "daily"
      ],
      "arm_group_label": [
            "mg"
      ],
      "other_name": [
            "zibotentan"
      ],
      "criteria": [
            "inclusion",
            "criterion",
            "men",
            "18",
            "year",
            "older",
            "confirm",
            "diagnosis",
            "prostate",
            "cancer",
            "bone",
            "metastasis",
            "exclusion",
            "criterion",
            "2",
            "prior",
            "chemotherapy",
            "regimen",
            "radiation",
            "chemotherapy",
            "bisphosphonates",
            "past",
            "4",
            "week"
      ],
      "gender": [
            "male"
      ],
      "minimum_age": [
            "18",
            "year"
      ],
      "maximum_age": [],
      "healthy_volunteers": false,
      "id": "NCT00055471.xml"
}